Spectrum Pharma Shares Hit New High on Q4 Results

11-03-2011 International Business TimesComments (0)

Biotechnology

Research and development expenses, a key overhead for pharmaceutical companies, rose to $7 million from $4 million, mainly due to in-licensing of compounds and continued investment in clinical trials. The company said the US Food and Drug ...

Read more on International Business Times

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top